B2B · research, clinic & peptide partners
Warm intros from people who already finished the GeneMap Research path.
They download their own AncestryDNA raw file, answer a short questionnaire, see a plain-language map, then opt in to meet a partner. You get a qualified conversation — not a cold list scrape.
Start a pilotWhat you get
- Opt-in leads only (DNA + questions + map first, intro second)
- Ancestry-file users who already spent money on DNA and completed the GeneMap Research path
- Pay per warm lead or first order (terms per deal)
- We stay informational — you own the research, clinical, or product conversation
Early signal (anonymized)
One real early user on file — partner-facing proof only. Not shown on the consumer apply form. Not a diagnosis.
Confirmed markers: TCF7L2 rs7903146 T/T · GC rs2282679 G/G
On file with a GLP-1-class therapy (tirzepatide): fasting glucose 171 → mostly mid-90s to low-140s; A1c 8.7% → estimated ~6.8–7.2% (lab draw still open); mood and “busy head” lifted; alcohol headaches resolved. Dizziness persists.
Gaps: AncestryDNA raw file not uploaded yet · no lab A1c / insulin / vitamin D / testosterone. Other variants (ADH1B, ALDH2, VDR, MTHFR) inferred only — not confirmed.
Consumer site callouts stay theme-level (no homepage rsIDs). The public sample report is live: See a sample report.
Literature links TCF7L2 T/T to stronger metabolic risk and often stronger GLP-1-class response — useful conversation fuel for research and clinic partners, not a GeneMap prescription.
Pilot shape
- 1
Align category
Which lanes you support — clinic partners, research partners, and peptide partners (including EU companies whose customers use products for research).
- 2
Cap a small lead batch
Fixed number of intros. Kill or scale on conversion.
- 3
Pay on proof
Invoice on accepted lead or first order — lock in writing before volume.
No fake pricing on this page. If the pilot can’t bill, we stop.
Partner inquiry